Jun Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jun Zhou has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Chian Zhao
Intelligent Medical Engineering, North Sichuan Medical College, Nanchong, Sichuan, China
1 shared publicationDanli Zhang
Department of Ultrasound Medicine, Dazhou Central Hospital, Dazhou, Sichuan, China
1 shared publication- Dongbing Li
Molecular Genetics Laboratory, Advanced Molecular Pathology Institute of Soochow University and SANO, Suzhou 215128, China
1 shared publication Fang Chen
Functional Department, Quxian County People's Hospital, Dazhou, Sichuan, China
1 shared publication- Fanxin Zeng
Department of Clinical Research Center, Dazhou Central Hospital and Institute of Basic Medicine and Forensic Medicine, North Sichuan Medical College, Nanchong, China
1 shared publication - Guo Huang
Department of Thyroid and Breast Surgery, Shenzhen Second People’s Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, China
1 shared publication
Latest Publications
- Open Access
- 20 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
A non-invasive end-to-end intelligent assistance system for breast ultrasound
Although artificial intelligence enhances medical image classification to effectively improve lesion diagnosis accuracy and efficiency, it still faces generalization challenges in breast ultrasound and its clinical potential remains underutilized in complex real-world scenarios. Here, we develop and test an end-to-end breast intelligent recognition device (BIRD) for women across diverse institution/population datasets. The accuracy of BIRD in the internal test set is 0.837 (95% confidence interval: 0.827-0.846), which significantly improves radiologists' accuracy in 2 reader studies (P < 0.05). BIRD is applied in breast cancer screening for 6,817 individuals and shows high consistency (Cohen's kappa: 0.702 (95% confidence interval: 0.628-0.777)) with clinical assessments in real-world application across 107 hospitals. Pathological and molecular subtype models developed using data from five hospitals also exhibit satisfactory classification performance. These findings confirm BIRD's ability to improve diagnostic accuracy, assist screening, and characterize breast lesions, facilitating clinical adoption in breast health practice. The Chinese Clinical Trial Register: ChiCTR2300073777.
- 20 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessA non-invasive end-to-end intelligent assistance system for breast ultrasound
Although artificial intelligence enhances medical image classification to effectively improve lesion diagnosis accuracy and efficiency, it still faces generalization challenges in breast ultrasound and its clinical potential remains underutilized in complex real-world scenarios. Here, we develop and test an end-to-end breast intelligent recognition device (BIRD) for women across diverse institution/population datasets. The accuracy of BIRD in the internal test set is 0.837 (95% confidence interval: 0.827-0.846), which significantly improves radiologists' accuracy in 2 reader studies (P < 0.05). BIRD is applied in breast cancer screening for 6,817 individuals and shows high consistency (Cohen's kappa: 0.702 (95% confidence interval: 0.628-0.777)) with clinical assessments in real-world application across 107 hospitals. Pathological and molecular subtype models developed using data from five hospitals also exhibit satisfactory classification performance. These findings confirm BIRD's ability to improve diagnostic accuracy, assist screening, and characterize breast lesions, facilitating clinical adoption in breast health practice. The Chinese Clinical Trial Register: ChiCTR2300073777.
- 1 November 2025
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 32 (37) , 8387-8399
Identification of Key Genes and Pathways in Lenvatinib-resistant Hepatocellular Carcinoma using Bioinformatic Analysis and Experimental Validation
Background: Resistance to lenvatinib poses a serious threat to the therapy of patients with Hepatocellular Carcinoma (HCC). The mechanism by which HCC develops resistance to lenvatinib is currently unknown. Objective: The aim of this study was to identify key genes and pathways involved in lenvatinib resistance in HCC using bioinformatic analysis and experimental validation. Methods: Differentially expressed genes (DEGs) were identified from the GSE186191 gene expression profile, comparing HCC cell lines with lenvatinib-resistant HCC cell lines. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were then carried out using DAVID. A protein-protein interaction network was constructed to visualize DEGs and identify hub genes. The expression and prognostic significance of these hub genes were further examined. Additionally, genomic enrichment analysis (GSEA) was utilized to investigate the potential functions of key genes. Following this, the presence of AHSG was validated in both the original Huh7 cells and the lenvatinib-resistant Huh7 (Huh7LR) cells resistant to lenvatinib through the utilization of quantitative real-time PCR (qRT-PCR). Results: A total of 232 DEGs were identified between HCC cell lines and those that are resistant to lenvatinib. These DEGs were significantly associated with arrhythmogenic right ventricular cardiomyopathy, hypertrophic cardiomyopathy, dilated cardiomyopathy, and mucin-type O-glycan biosynthesis. Three hub genes, including AHSG, C6, and ORM1, were identified. The low expression of AHSG showed a poorer prognosis in HCC. GSEA demonstrated a significant correlation between low AHSG expression and pathways involving fatty acid metabolism, ribosome function, glycine, serine, and threonine metabolism, peroxisome activity, and bile acid biosynthesis. The expression of AHSG was notably reduced in Huh7LR cells (p = 0.006) compared to Huh7 cells. Conclusion: Diminished AHSG expression is strongly associated with lenvatinib resistance in HCC, suggesting that it may have implications for developing effective strategies to overcome this resistance.
- 1 November 2025
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 32 (37) , 8387-8399
Identification of Key Genes and Pathways in Lenvatinib-resistant Hepatocellular Carcinoma using Bioinformatic Analysis and Experimental Validation
Background: Resistance to lenvatinib poses a serious threat to the therapy of patients with Hepatocellular Carcinoma (HCC). The mechanism by which HCC develops resistance to lenvatinib is currently unknown. Objective: The aim of this study was to identify key genes and pathways involved in lenvatinib resistance in HCC using bioinformatic analysis and experimental validation. Methods: Differentially expressed genes (DEGs) were identified from the GSE186191 gene expression profile, comparing HCC cell lines with lenvatinib-resistant HCC cell lines. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were then carried out using DAVID. A protein-protein interaction network was constructed to visualize DEGs and identify hub genes. The expression and prognostic significance of these hub genes were further examined. Additionally, genomic enrichment analysis (GSEA) was utilized to investigate the potential functions of key genes. Following this, the presence of AHSG was validated in both the original Huh7 cells and the lenvatinib-resistant Huh7 (Huh7LR) cells resistant to lenvatinib through the utilization of quantitative real-time PCR (qRT-PCR). Results: A total of 232 DEGs were identified between HCC cell lines and those that are resistant to lenvatinib. These DEGs were significantly associated with arrhythmogenic right ventricular cardiomyopathy, hypertrophic cardiomyopathy, dilated cardiomyopathy, and mucin-type O-glycan biosynthesis. Three hub genes, including AHSG, C6, and ORM1, were identified. The low expression of AHSG showed a poorer prognosis in HCC. GSEA demonstrated a significant correlation between low AHSG expression and pathways involving fatty acid metabolism, ribosome function, glycine, serine, and threonine metabolism, peroxisome activity, and bile acid biosynthesis. The expression of AHSG was notably reduced in Huh7LR cells (p = 0.006) compared to Huh7 cells. Conclusion: Diminished AHSG expression is strongly associated with lenvatinib resistance in HCC, suggesting that it may have implications for developing effective strategies to overcome this resistance.
- 31 October 2022
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 25 (3) , 578-591
Roles of oncogenes in esophageal squamous cell carcinoma and their therapeutic potentials
- 31 October 2022
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 25 (3) , 578-591
Roles of oncogenes in esophageal squamous cell carcinoma and their therapeutic potentials